Pennant Group
Pennant Group's revenue rose 36.3% to $948 million in fiscal 2025. Its operating margin was 5.5%, about the same as 5.5% a year earlier. Free cash flow was $36 million, up 19.6%. The diluted share count rose 10.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Pennant Group does
Pennant Group provides home health, hospice and senior living services in the United States. It runs home health and hospice through 172 agencies and senior living through 63 communities that offer assisted living, independent living and memory care. It operates in sixteen states and provides operational support in Connecticut.
It reports two segments: home health and hospice, which also includes home care and geriatric primary and palliative care, and senior living. It gets revenue from Medicare and Medicaid, private-pay patients and residents, and managed care payors. Medicare supplied 48.4% of its revenue in 2025. The 10-K says healthcare is local and that Pennant gives its local leaders the authority to run each operation, with support from a service center.
Pennant became a separate company in 2019 when The Ensign Group spun it off. Payroll is its main expense.
Its biggest risks, as it describes them
- Medicare reimbursement changes could cut its revenue.
- Cuts to Medicaid payment rates or rule changes could hurt it.
- Competition for nurses and caregivers could raise its labor costs.
- It may be unable to acquire or open operations on good terms.
- Government audits and investigations, and rules for healthcare providers, could bring penalties.
Income statement
From fiscal 2017 to 2025, earnings per share grew 11.2% a year and net income 14.7% a year, as new shares raised the share count by 27% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 5 | 2 | 6 | 24 | 17 |
| Debt incl. finance leases | 51 | 63 | 64 | 1 | 176 |
| Net debt (negative means net cash) | 46 | 61 | 58 | −23 | 158 |
| Net debt to EBITDA | 4.9x | 3.5x | 1.9x | −0.5x | 2.6x |
| Debt to equity | 0.5x | 0.5x | 0.4x | 0.0x | 0.5x |
| Interest coverage | 2.4x | 3.3x | 4.2x | 5.5x | 7.8x |
| Current ratio | 1.1x | 1.1x | 1.1x | 1.2x | 1.1x |
| Quick ratio | 1.1x | 1.1x | 1.1x | 1.2x | 1.1x |
Cash flow
Projections
Project Pennant Group's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Pennant Group shares on the open market, and 3 insiders sold $690,087, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Brent GuerisoliChief Executive Officer | Sold plan | 4,285 | $38.52 | $165,058 | Form 4 |
| Aug 6, 2026 | Jason Paul SteikChief Clinical Officer | Sold plan | 1,394 | $38.52 | $53,697 | Form 4 |
| Aug 6, 2026 | Kirk Sterling CheneyEVP, GC and Corp Secy | Sold plan | 1,393 | $38.52 | $53,658 | Form 4 |
| Jul 10, 2026 | Brent GuerisoliChief Executive Officer | Sold plan | 3,159 | $41.57 | $131,320 | Form 4 |
| Jul 7, 2026 | Brent GuerisoliChief Executive Officer | Sold plan | 3,165 | $40.51 | $128,214 | Form 4 |
| May 22, 2026 | Brent GuerisoliChief Executive Officer | Sold plan | 4,508 | $35.08 | $158,140 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 8 | 7 of 8 | 5 of 8 |
| Rule of 40 | 19.7% | 31.9% | 40.1% |
| Altman Z'' | 1.01 | 1.75 | 1.45 |
| Accruals ratio | −3.8% | −2.8% | −2.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 6 of 8 | 7 of 8 | 5 of 8 |
Compare
Put Pennant Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Pennant Group | FY25 | 36.3% | 5.5% | 3.8% | 9.3% | 2.6x | 5 | |
| CorVel | FY26 | 7.0% | — | 11.5% | — | — | — | Compare |
| Myriad Genetics | FY25 | −1.6% | −47.0% | −1.7% | −62.6% | — | 5 | Compare |
| Sotera Health | FY25 | 5.7% | — | 12.8% | 6.7% | — | 7 | Compare |
| NeoGenomics Laboratories | FY25 | 10.1% | −15.9% | −3.0% | −8.8% | — | 5 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 251 | 286 | 338 | 391 | 440 | 473 | 545 | 695 | 948 |
| Revenue growth | — | 14.0% | 18.3% | 15.5% | 12.5% | 7.6% | 15.1% | 27.6% | 36.3% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — | — | — |
| Operating income | 15 | 21 | 6 | 19 | 5 | 13 | 25 | 38 | 52 |
| Net income | 10 | 16 | 2 | 16 | 3 | 7 | 13 | 23 | 30 |
| Diluted EPS (US$) | 0.36 | 0.58 | 0.11 | 0.52 | 0.09 | 0.22 | 0.44 | 0.70 | 0.84 |
| Diluted shares (millions) | 28 | 28 | 30 | 30 | 31 | 30 | 30 | 32 | 35 |
| Cash flow | |||||||||
| Cash from operations | 17 | 23 | 10 | 50 | −18 | 9 | 33 | 39 | 48 |
| Capital expenditure | 3 | 4 | 7 | 7 | 6 | 14 | 8 | 9 | 12 |
| Free cash flow | 14 | 20 | 3 | 43 | −25 | −5 | 25 | 30 | 36 |
| Dividends paid | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 12 | 5 | 19 | 33 | 14 | 10 | 21 | 48 | 204 |
| Stock-based compensation | 2 | 2 | 3 | 8 | 10 | 3 | 5 | 8 | 9 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 0 | 0 | 0 | 0 | 5 | 2 | 6 | 24 | 17 |
| Debt incl. finance leases | — | 0 | 18 | 8 | 51 | 63 | 64 | 1 | 176 |
| Total assets | — | 98 | 448 | 507 | 530 | 512 | 540 | 680 | 968 |
| Total liabilities | — | 33 | 377 | 406 | 416 | 386 | 394 | 368 | 594 |
| Shareholders' equity | 60 | 65 | 71 | 101 | 114 | 126 | 146 | 312 | 374 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | 6.1% | 7.2% | 1.7% | 4.8% | 1.1% | 2.7% | 4.6% | 5.5% | 5.5% |
| Net margin | 3.9% | 5.5% | 0.8% | 4.0% | 0.6% | 1.4% | 2.5% | 3.2% | 3.1% |
| Free cash flow margin | 5.6% | 6.9% | 0.8% | 11.0% | −5.6% | −1.1% | 4.6% | 4.4% | 3.8% |
| Rule of 40 (growth + FCF margin) | — | 20.9% | 19.2% | 26.5% | 6.9% | 6.5% | 19.7% | 31.9% | 40.1% |
| Return on capital | — | — | 4.4% | 16.6% | 2.7% | 6.0% | 9.2% | 12.0% | 9.3% |
| Return on equity | — | — | 3.7% | 18.3% | 2.5% | 5.5% | 9.9% | 9.9% | 8.6% |
| Return on assets | — | — | 0.9% | 3.3% | 0.5% | 1.3% | 2.5% | 3.7% | 3.6% |
| Net debt to EBITDA | — | −0.0x | 1.9x | 0.3x | 4.9x | 3.5x | 1.9x | −0.5x | 2.6x |